Skip to content

Pain Reduction Through Empowered Recovery (PRIME) Study

Testing an Intervention to Reduce Pain and Depression Among Older Women With Physical Disabilities

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05619510
Acronym
PRIME
Enrollment
9
Registered
2022-11-17
Start date
2023-03-31
Completion date
2026-06-01
Last updated
2026-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Depressive Symptoms, Disability Physical, Pain, Chronic

Brief summary

Chronic pain and depression or low mood are often experience by women who age with or into disabilities. Due to various factors women with disabilities often experience this cycle of pain and depression. Both of these conditions can be debilitating and lead to declines in health. Treating these conditions simultaneously, particularly , in older adults can be complicated due to side effects, risks of poor access to pain management and mental health care , and complications from other co occuring conditions. In order to address this cycle in older women with disabilities the investigators are testing the Women in Pain Reduction through Improved Mood and Empowerment (PRIME) study. The PRIME intervention includes four in person visits by a nurse to the women's homes where the participants set goals regarding pain and depression and the nurse helps the participants strategize ways to meet these goals. The second component of the study will be eight group sessions virtually with other participants in the study. The group sessions will be led by a clinical psychologist who will engage in Acceptance Commitment Therapy with the women.

Detailed description

Chronic pain and depression frequently co-occur among older women with disabilities, and each can exacerbate the other in a worsening cycle. This co-occurrence may be due, in part, to pain and depression sharing biologic etiologies such as inflammation. Beyond each individual category of risk, the intersection of age, sex, and disability place older women with disabilities at even higher risk of having co-occurring pain and depression.There are several effective multi-component behavioral interventions for either pain or depression, but not both outcomes in combination, and none were designed to integrate social determinants of health to address the inequities inherent in being an older woman with disabilities. Addressing these two conditions in this population warrants multicomponent interventions that are appropriate for and inclusive of all older women with disabilities. The proposed study is to apply self-regulation theory to refine and further test the feasibility of a tailored behavioral activation intervention, older women with disabilities in Pain Reduction through Improved Mood and Empowerment (PRIME) Study Aim 1: Leveraging the investigators previous research, the investigators will enroll 15-30 community dwelling women , ages 50 and over, with physical disabilities , living in Maryland who have pain and depression in the Women in PRIME clinical trial. Aim 2: The investigators will determine a) feasibility and acceptability of the intervention and b) if strategies and evaluation techniques are appropriate.

Interventions

BEHAVIORALPRIME Intervention

Participants who are randomized to the intervention will participate in five virtual or in person visits with a nurse where the nurse uses self regulation theory as a guide to help them set their own goals surrounding pain and depression and use tailored strategies to address these goals. The second component will include six virtual Acceptance Commitment Therapy (ACT) sessions, led by a clinical psychologist. There will be 3-5 other research participants in the sessions.

Sponsors

Johns Hopkins University
Lead SponsorOTHER
National Institute on Aging (NIA)
CollaboratorNIH
Cornell University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

The data collectors, interventionists, and investigator will be masked to which group participants belong to.

Intervention model description

A wait list control group will be used for this study. Participants will be randomized to either the intervention group or the wait list control group. Participants in the intervention group will start the intervention immediately. Participants in the wait list control will start after 2-3 months.

Eligibility

Sex/Gender
FEMALE
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* self-reported pain \>4 out of a 0-10 scale that has lasted longer than 3 months and prohibits at least one valued or daily activity, * physical disability based on the 2008 American Community Survey. The survey includes one question about disability in the following categories: sensory, physical, self-care, ability to go outside of the home, and independent living difficulty. Candidates who report having mobility disabilities will be considered for the study, * non-institutionalized and living in Maryland, and * score a 5 or higher on the PHQ9 (depression measure) at least two times during a two week period (screening call and then at first data collection visit via video) * 50 years of age and older, 6) female

Exclusion criteria

* hospitalized \> 3 times in the last year, * participating in physical therapy, * have a terminal diagnosis (\<1 year expected survival), * \> moderate intellectual impairment (5-7 errors) based on the Short Portable Mental Status Questionnaire (SPMSQ), 81 and * unable to understand or speak English. We will exclude anyone with more than three hospitalizations and/or have a terminal diagnosis because of the acuity of their conditions which may limit the effectiveness of the intervention. Physical therapy may impact the outcomes of the intervention and having impaired cognition may make it difficult for participants to engage in the nurse visits, set goals and participate in the ACT sessions.

Design outcomes

Primary

MeasureTime frameDescription
Pain Intensity as Assessed by the Patient-Reported Outcomes Measurement Information System Pain Intensity MeasureBaseline and 12 weeksPain Intensity was measured by the Patient-Reported Outcomes Measurement Information System . Pain intensity measure. Patient-Reported Outcomes Measurement Information System . Survey uses a standardized T-score metric based on a mean of 50 and a standard deviation of 10. Higher score worse pain.
Pain Interference as Assessed by Patient-Reported Outcomes Measurement Information System (PROMIS)Baseline and 12 weeks.Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference is a 6 question measure with a range of 0-100 with a higher score indicating increased pain interference.
Pain Behavior as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS)Pain Behavior MeasureBaseline and 12 weeks.Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference is a 20 question measure with a range of 20-100 with a higher score indicating increased pain behaviors
Depression as Assessed by the Patient Health Questionnaire 9 (PHQ9)Baseline and 12 weeks.The Patient Health Questionnaire 9 (PHQ9) measures depressive symptoms. The score range is 0-27 with a higher score indicating more severe depression.
Depression as Assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) 57Baseline and 12 weeksThe Patient Reported Outcomes Measurement System (PROMIS)57 the Patient Reported Outcomes Measurement Information System (PROMIS) 57, which is includes an 8-item instrument that can be used to measure self-reported negative mood, view of self, and somatic symptoms. The score range for PROMIS 57 is 8-40. Higher scores indicate more depressive symptoms, which is a worse outcome.

Secondary

MeasureTime frameDescription
Psychological Flexibility as Assessed by the Psychological Flexibility in Pain InstrumentBaseline and 12 weeks. Baseline are pre intervention scores and 12 weeks are post intervention scores.The Psychological Flexibility in Pain Instrument will be used. The ability to act in alignment of goals, values and in acceptance while living with pain and distress.The Psychological Inflexibility in Pain Scale (PIPS) is a 12-item scale measuring avoidance of pain, and fusion with pain thoughts. Scores range from 7-84 with a higher score indicating increased psychological inflexibility in pain.
Percentage of Goals Attained as Assessed by Self Report12 weeksSelf-report if goals were achieved fully, partially or not at all. 23 goals were set.
Comorbidities as Assessed by the Charlson Comorbidity Index (CCI)BaselineThe Charlson Comorbidity Index will be used to obtain a score for number of chronic conditions from 19 categories.The CCI consists of 19 selected conditions that are weighted and summed to an index on a 0-33 scale. Higher scores indicate more comorbidities.
Change in Sleep Disturbance as Assessed by the 4 Item PROMIS Sleep Disturbance MeasureBaseline and 12 weeksSleep disturbance will be measured using the 4 item PROMIS sleep disturbance measure. This six item scale is used to measure sleep disturbances in the past 7 days and the range is 6 -30 with higher scores indicating more sleep disturbances.
Communication With Health Care Providers- Patient Reaction AssessmentBaseline and 12 weeksThe Patients' Reaction Assessment has a 5-item subscale used to measure perceived ability to communicate with providers. The sub scale on perceived ability to communicate with providers can have scores ranging from 0-35 with higher scores indicating higher perceived ability to communicate.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJaniece L Taylor, PhD

Johns Hopkins School of Nursing

STUDY_CHAIRElaine Wethington, PhD

Cornell Roybal Center (Weill Cornell Medicine)

Participant flow

Recruitment details

Participants were recruited for the study through community partners, including churches, and senior day centers, and Johns Hopkins MyChart. Investigators also recruited through word of mouth and previous research studies.

Baseline characteristics

Characteristic
Age, Continuous64.04 years
STANDARD_DEVIATION 2.01
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
1 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
6 Participants
Sex: Female, Male
Female
5 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 50 / 4
other
Total, other adverse events
0 / 50 / 4
serious
Total, serious adverse events
0 / 50 / 4

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 12, 2026